Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

An Open Label,Observational, Real Time Data Capturing of Usage & Outcome of Coseal

12 de octubre de 2012 actualizado por: Dr. Ali Zamir Khan, Medanta, The Medicity, India

An Open- Label,Multicentre, Observational, Prospective, Real-time Data Capturing of Usage, Outcome & Physician Satisfaction of Coseal in Cardio- Vascular- Thoracic Operative and Re- Operative Procedures

This study is Open- Label, Observational, Prospective, Real-time data capturing of Usage, Outcome & Physician satisfaction of Coseal in Cardio- Vascular-Thoracic Operative and Re- Operative procedures.

Objective of this study is to assess current practice pattern and best practice sharing of usage of Coseal by collecting data on (1) Sealing suture lines along arterial and venous reconstruction(2) Patients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture lines in lung resection procedures (3) From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery.

Number of expected patient enrollment is 750 from 20 participating sites.

Descripción general del estudio

Estado

Desconocido

Condiciones

Descripción detallada

Objectives:

  • Assessing current practice pattern and best practice sharing of usage of Coseal as per IFU by collecting data on oSealing suture lines along arterial and venous reconstructions oPatients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture and staple lines in lung resection procedures
  • From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery
  • To possibly create a guideline for usage of Sealant in routine practice in India
  • To study delivery methods and clinical impact in minimally invasive surgery like VATS and robotic surgery

End points

Primary Endpoint

  1. Cardio vascular sealing:

    To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding average time to achieve hemostasis for a single bleeding site after 60 s of clamping without manual compression In case of sternotomy, Hemostasis time in mns, which is operative time comprised between the removal of cardio-pulmonary bypass cannulae and the closure of the sternum.

    Overall postoperative bleeding in mL/m² revision for bleeding Minor complications, major complications, mortality

  2. Efficacy of Coseal in prevention or reduction of adhesion in re-do surgeries for patients with staged operations for congenital cardiac malformation re-operated on during the follow-up period of the registry

    Incidence of adhesions. location and extension of adhesion by measuring the percentage of surface affected for each of the following regions: pericardial or retrosternal, inferior or diaphragmatic region, right lateral or atrial region, region around the great vessels, pulmonary surface.

    Overall evaluation (dissection easy or difficult) Incidence of subjects free of adhesions.

    Severity (at each of these sites, the adhesions will be graded as follows:

    absence of adhesion; 1: filmy and avascular; 2: dense and/or vascular; and 3: cohesive)

  3. Air leak: incidence of immediate (at the time of closure) and prolonged post-operative air leak, Use in redo surgery for air leak.

Secondary Endpoints

  1. Cardiovascular (sealing and adhesion prevention):

    1. Total operative time
    2. Nature and duration of first operation
    3. Nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
    4. Length of intensive care stay
    5. Length of hospital stay
    6. Infection rate
    7. Quality of wound healing
    8. Quality of life (SF36)
  2. Thoracic and Lung

    1. Sealing the suture/ staple line on table Use of buttressing
    2. Total operative time
    3. Drain output
    4. Drain duration
    5. Length of hospital stay
    6. Prolonged air leak (more than 5 days) (>5 days is the new standard for prolonged aire leak accepted in 2011 by the EU Soc of CVTS, see ref.)
    7. Infection rate
  3. In all cases,

    1. intra and post-operative blood loss
    2. FFP, Transfusion
    3. Reoperation for bleeding purpose
  4. Others

    1. Surgeons satisfaction
    2. Easiness of product handling during application (VAS)

Tipo de estudio

De observación

Inscripción (Anticipado)

750

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Haryana
      • Gurgaon, Haryana, India, 122 001
        • Medanta, The Medicity

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patient falling under inclusion criteria can take part in to bthe study

Descripción

Inclusion Criteria:

  1. Patients undergoing cardiovascular and thoracic surgery who require use of Coseal as a treatment strategy.
  2. Patient undergoing open, Video Assisted surgery and robotic surgery to be included and analysed as subgroups
  3. Written informed consent obtained from the patient or legal representative for data collection post surgery in patients who had Coseal used intraoperatively (data privacy laws).

Exclusion Criteria:

  1. Known hypersensitivity to components of the investigational product
  2. Known Immune system disorders, immunodeficiency
  3. Concomitant use of any other anti-adhesion product
  4. Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
  5. Unplanned re-operation in case of use for anti-adhesion
  6. Contraindications for use of Coseal

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cardio Vascular Outcome
Periodo de tiempo: 18 months
To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding
18 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cardiovascular (sealing and adhesion prevention):
Periodo de tiempo: 18 months
To Capture total operative time,nature and duration of first operation,nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
18 months
Thoracic and Lung (Sealing and Adhesion prevention)
Periodo de tiempo: 18 months
18 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Dr. Ali Z Khan, MS,FRCS,FRCS, Medanta, The Medicity

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de diciembre de 2012

Finalización primaria (Anticipado)

1 de noviembre de 2013

Finalización del estudio (Anticipado)

1 de mayo de 2014

Fechas de registro del estudio

Enviado por primera vez

8 de octubre de 2012

Primero enviado que cumplió con los criterios de control de calidad

12 de octubre de 2012

Publicado por primera vez (Estimar)

15 de octubre de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

15 de octubre de 2012

Última actualización enviada que cumplió con los criterios de control de calidad

12 de octubre de 2012

Última verificación

1 de octubre de 2012

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MM/CTVS/2012/001

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir